US2009324608A1PendingUtilityA1

Novel human protein kinase, phosphatase, and protease family members and uses thereof

Assignee: MILLENNIUM PHARM INCPriority: Feb 29, 2000Filed: Sep 5, 2007Published: Dec 31, 2009
Est. expiryFeb 29, 2020(expired)· nominal 20-yr term from priority
C12N 9/1205C12N 9/12C12Q 1/6886C07K 16/40C12N 9/6472C12Q 2600/156A61K 38/00C12Q 2600/136C12N 9/16C12N 9/48C12N 9/6424C12N 9/6427C12Q 2600/106
61
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The invention provides isolated nucleic acids molecules, designated 53070, 15985, 26583, 21953, m32404, 14089, and 23436 nucleic acid molecules, which encode novel human protein kinase family members, serine/threonine protein kinase family members, serine/threonine phosphatase family members, prolyl oligopeptidase family members, trypsin family members, trypsin serine protease family members, and ubiquitin protease family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 53070, 15985, 26583, 21953, m32404, 14089, or 23436 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 53070, 15985, 26583, 21953, m32404, 14089, or 23436 gene has been introduced or disrupted. The invention still further provides isolated 53070, 15985, 26583, 21953, m32404, 14089, or 23436 proteins, fusion proteins, antigenic peptides and anti-53070, 15985, 26583, 21953, m32404, 14089, or 23436 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.

Claims

exact text as granted — not AI-modified
1 . An isolated nucleic acid molecule selected from the group consisting of:
 a) a nucleic acid comprising the nucleotide sequence of SEQ ID NO:1, 3, 7, 9, 14, 16, 19, 21, 24, 26, 33, 35, 40, or 42; and   b) a nucleic acid molecule which encodes a polypeptide comprising the amino acid sequence of SEQ ID NO:2, 8, 15, 20, 25, 34, or 41.   
     
     
         2 . The nucleic acid molecule of  claim 1 , further comprising vector nucleic acid sequences. 
     
     
         3 . The nucleic acid molecule of  claim 1 , further comprising nucleic acid sequences encoding a heterologous polypeptide. 
     
     
         4 . A host cell which contains the nucleic acid molecule of  claim 1 . 
     
     
         5 . An isolated polypeptide comprising the amino acid sequence of SEQ ID NO:2, 8, 15, 20, 25, 34, or 41. 
     
     
         6 . The polypeptide of  claim 5  further comprising heterologous amino acid sequences. 
     
     
         7 . An antibody or antigen-binding fragment thereof that selectively binds to a polypeptide of  claim 5 . 
     
     
         8 . A method for producing a polypeptide comprising the amino acid sequence of SEQ ID NO:2, 8, 15, 20, 25, 34, or 41, the method comprising culturing the host cell of  claim 4  under conditions in which the nucleic acid molecule is expressed. 
     
     
         9 . A method for detecting the presence of a polypeptide of  claim 5  in a sample, comprising:
 a) contacting the sample with a compound which selectively binds to the polypeptide; and   b) determining whether the compound binds to the polypeptide in the sample.   
     
     
         10 . The method of  claim 9 , wherein the compound which binds to the polypeptide is an antibody. 
     
     
         11 . A kit comprising a compound which selectively binds to a polypeptide of  claim 5  and instructions for use. 
     
     
         12 . A method for detecting the presence of a nucleic acid molecule of  claim 1  in a sample, comprising the steps of:
 a) contacting the sample with a nucleic acid probe or primer which selectively hybridizes to the nucleic acid molecule; and   b) determining whether the nucleic acid probe or primer binds to a nucleic acid molecule in the sample.   
     
     
         13 . The method of  claim 12 , wherein the sample comprises mRNA molecules and is contacted with a nucleic acid probe. 
     
     
         14 . A kit comprising a compound which selectively hybridizes to a nucleic acid molecule of  claim 1  and instructions for use. 
     
     
         15 . A method for identifying a compound which binds to a polypeptide of  claim 5  comprising the steps of:
 a) contacting a polypeptide, or a cell expressing a polypeptide of  claim 5  with a test compound; and   b) determining whether the polypeptide binds to the test compound.   
     
     
         16 . A method for modulating the activity of a polypeptide of  claim 5 , comprising contacting a polypeptide or a cell expressing a polypeptide of  claim 5  with a compound which binds to the polypeptide in a sufficient concentration to modulate the activity of the polypeptide. 
     
     
         17 . A method of inhibiting aberrant activity of a 53070-, 15985-, 26583-, 21953-, m32404-, 14089-, or 23436-expressing cell, comprising contacting a 53070-, 15985-, 26583-, 21953-, m32404-, 14089-, or 23436-expressing cell with a compound that modulates the activity or expression of a polypeptide of  claim 5 , in an amount which is effective to reduce or inhibit the aberrant activity of the cell. 
     
     
         18 . The method of  claim 17 , wherein the compound is selected from the group consisting of a peptide, a phosphopeptide, a small organic molecule, and an antibody. 
     
     
         19 . A method of treating or preventing a disorder characterized by aberrant activity of a 53070-, 15985-, 26583-, 21953-, m32404-, 14089-, or 23436-expressing cell, in a subject, comprising:
 administering to the subject an effective amount of a compound that modulates the activity or expression of a nucleic acid molecule of  claim 1 , such that the aberrant activity of the 53070-, 15985-, 26583-, 21953-, m32404-, 14089-, or 23436-expressing cell is reduced or inhibited.

Join the waitlist — get patent alerts

Track US2009324608A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.